炬光科技(688167.SH):競爭對手也在通過降低售價的方式挑戰公司的優勢地位
格隆匯5月5日丨有投資者向炬光科技(688167.SH)提問:FAC產品在份額比較大的情況下,為何還會面臨降價壓力?
炬光科技回覆:我們FAC產品在國內光纖激光器市佔率大概在60%左右,競爭對手主要是一家瑞士公司。價格壓力一方面是受宏觀經濟影響,2022年下游光纖激光器市場並不景氣,下游的市場壓力、價格壓力在下半年起逐步傳導到元器件層面,且該壓力在2023年尚未緩解。另外一方面,競爭對手也在通過降低售價的方式挑戰公司的優勢地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.